Month: April 2021

Strong sales momentum and very positive market trends Outlook for double-digit, profitable growth confirmedSolutions 30 SE, the European leader in solutions for new technologies, today disclosed its revenue for the first quarter of 2021.In millions of euros Q1 2021 Q1 2020 % changeTotal 225.2 189.3 +19.0%From France 142.1 116.4 +22.1%From Benelux 37.0 34.8 +6.3%From other countries 46.1 38.1 +21.0%Data for the Q1 2020 have been restated to consolidate Worldlink as of January 1, 2020. Solid growth trend continues Consolidated revenue Solutions 30’s consolidated revenue for the first quarter of 2021 amounted to €225.2 million, up +19.0% (+15.4% organic growth) compared to the same period in 2020. The group’s maintenance business, which is recurrent in nature, represents 58% of the group’s revenue. As in 2020, positive...

Operational performance remains extremely resilientRevenue grew by 18% to €819.3 million EBITDA margin increases to 13.0% Net cash position of €59.2 millionAccelerating the group’s transformationFoundations reinforced to consolidate growthLong-term outlook confirmedPotential for growth underpinned by the digital transformation and the energy transition, and bolstered by European recovery plansSolutions 30 SE today announces its consolidated earnings for the financial year ended December 31. The Supervisory Board of Solutions 30, meeting on April 27, examined and approved the financial results for 2020, as approved by the Group Management Board. These results are still being audited. The complete consolidated financial statements, including the notes, will be made available as soon as possible. The financial presentation...

— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693067) — Systemic administration of PV-10 for treatment of solid tumor cancers KNOXVILLE, TN, April 28, 2021 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that two abstracts about data from clinical and preclinical study of investigational cancer immunotherapy PV-10 (rose bengal disodium) were accepted for the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, which will be held June 4-8 online. Abstract #1:Title: Phase I study of autolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium Session Title: Poster Session: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary Abstract number for publication: 4115This clinical...

Marked return to growth Q1 turnover: €593.8 millionin € million Q1 2021 Q1 2020 Change  France 250.5 271.9 -7.9%International 343.3 304.6 +12.7%       Total  593.8  576.5 +3.0%The SYNERGIE Group has begun 2021 with a marked return to growth, posting consolidated turnover on a like for like basis of €593.8 million (+3% compared with 2020). This performance was achieved thanks to the strategy implemented in France and in all the countries in which the Group operates, enabling it to conquer new markets in high-growth sectors (logistics, call centres, healthcare, agri-food, environment, digital and activities related to the transformation of cities). During the quarter, activity was again boosted by International, which strengthened its positions in both Northern Europe (+5%) and Southern Europe (+21.2%), where Italy played...

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traitement avec PXT3003 chez les patients atteints de la maladie de Charcot-Marie-Tooth de type 1A (CMT1A) Les nouveaux résultats suggèrent un bon profil de sécurité et une efficacité durable de PXT3003, évaluée sur l’échelle ONLS (Overall Neuropathy Limitation Scale), après une durée totale de 4 ans et demi d‘essai clinique Une conférence téléphonique et un webinar se tiendront demain jeudi 29 avril à 14h00 CET (8h00 ET) PARIS, France, le 28 avril 2021 à 18h00 (CET) – Pharnext SA (FR0011191287 – ALPHA) (« La Société »), société biopharmaceutique à un stade clinique avancé, pionnière d’une nouvelle approche de développement de combinaisons de médicaments innovantes basée sur les Big Data génomiques et l’intelligence...

Press releaseParis, 28 April 2021 NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA Orange prices its 500 million euro, undated, 8-year non-call, deeply subordinated fixed to reset rate notes Orange S.A. (the Company) successfully priced its issuance of €500,000,000 undated 8 year non-call deeply subordinated fixed to reset rate notes with a fixed coupon of 1.375% until the first call date (the Notes). The Notes are scheduled to be admitted to trading on Euronext Paris. It is also expected that rating agencies assign the New Notes a rating of Baa3/BBB- (Moody’s/ S&P) and an equity content of 50%. The Company also launched a tender offer (the Tender Offer) to repurchase its:€1,000,000,000 Undated 7 Year Non-Call Deeply Subordinated Fixed to Reset Rate Notes with first call date on 1 October 2021 (of which €118,374,000 is...

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’) New results suggest good safety profile and sustained efficacy of PXT3003 as measured with the Overall Neuropathy Limitation Scale (‘ONLS’), after 4.5 years of total trial time. A live conference call and webcast will be held tomorrow, Thursday April 29that 2:00 p.m. CET (8:00 a.m. ET) PARIS, France, April 28, 2021, 6:00 p.m. CET – Pharnext SA (FR0011191287 – ALPHA) (the ‘Company’), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY™ platform, today announces new results from an interim analysis of an ongoing open-label...

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’) New results suggest good safety profile and sustained efficacy of PXT3003 as measured with the Overall Neuropathy Limitation Scale (‘ONLS’), after 4.5 years of total trial time. A live conference call and webcast will be held tomorrow, Thursday April 29that 2:00 p.m. CET (8:00 a.m. ET) PARIS, France, April 28, 2021, 6:00 p.m. CET – Pharnext SA (FR0011191287 – ALPHA) (the ‘Company’), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY™ platform, today announces new results from an interim analysis of an ongoing open-label...

Helstu niðurstöðurFramlegð af vöru- og þjónustusölu nam 5.144 millj. kr. samanborið við 4.304 millj. kr. á 1F 2020, sem samsvarar 19,5% hækkun milli ára. EBITDA nam 1.505 millj. kr. samanborið við 1.021 millj. kr. á 1F 2020, sem jafngildir 47,5% hækkun. Framlegð af vörusölu var 24,6% á 1F 2021 en framlegðin var 22,9% á sama fjórðungi árið áður. Kostnaður vegna COVID-19 var 37 millj. kr. á 1F 2021 en var 48 millj. kr. á sama fjórðungi árið áður. Eigið fé í lok 1F 2021 var 29.227 m.kr. og eiginfjárhlutfall 34,8% samanborið við 35,7% í lok árs 2020. Nettó vaxtaberandi skuldir án leiguskuldbindinga var 30.276 millj. kr. í lok 1F 2021 samanborið við 29.986 millj. kr. í lok 2020. EBITDA spá félagsins fyrir árið 2021 er hækkuð um 400 millj. kr. og er nú 7.900 – 8.300 millj. kr. Eggert Þór Kristófersson, forstjóri Festi: Niðurstaða...

UPM-Kymmene Corporation        Stock Exchange Release (Managers’ Transactions) 28 April 2021 at 18:00 EEST UPM-Kymmene Corporation: Managers’ Transactions (Brunow)  On 30 March 2021, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company’s Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members’ behalf, and the rest in cash. In accordance with this resolution, a total of 1,710 shares have been purchased to Berndt Brunow as follows:  Person subject to the notification requirementName: Brunow, BerndtPosition: Deputy Chair of the BoardIssuer: UPM-Kymmene CorporationLEI: 213800EC6PW5VU4J9U64 Notification type: INITIAL NOTIFICATION____________________________________________ Transaction...